Generic Alinia is used to treat diarrhea caused by certain parasites. ANI Pharmaceuticals is introducing nitazoxanide tablets ...

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free ...

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research ...

PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets ...

ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the ...

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full ...

ANI Pharmaceuticals (ANIP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's ...

Fintel reports that on March 12, 2025, JP Morgan initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Overweight recommendation. Analyst Price Forecast Suggests 27.63% Upside As of March 4 ...

J.P. Morgan on Wednesday launched its coverage of ANI Pharmaceuticals (NASDAQ:ANIP) with an Overweight recommendation and a year-end price target of $85 per share, citing the specialty pharma ...

As of March 4, 2025, the average one-year price target for ANI Pharmaceuticals is $80.75/share. The forecasts range from a low of $62.62 to a high of $98.70. The average price target represents an ...

4 analysts have expressed a variety of opinions on ANI Pharmaceuticals (NASDAQ:ANIP) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...